{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolism%2C+Inborn+Errors&page=9",
    "query": {
      "condition": "Metabolism, Inborn Errors",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1608,
    "total_pages": 161,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolism%2C+Inborn+Errors&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolism%2C+Inborn+Errors&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T12:29:00.451Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06247085",
      "title": "Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Homocystinuria"
      ],
      "interventions": [
        {
          "name": "Pegtibatinase",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2023-12-28",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06247085"
    },
    {
      "nct_id": "NCT04655911",
      "title": "A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mucopolysaccharidosis III-B"
      ],
      "interventions": [
        {
          "name": "ABO-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abeona Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2020-10-28",
      "completion_date": "2022-04-07",
      "has_results": false,
      "last_update_posted_date": "2022-05-31",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04655911"
    },
    {
      "nct_id": "NCT05289544",
      "title": "Phone-Based Based Walk With Ease Program for Adults With Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Arthritis",
        "Gout",
        "Fibromyalgia",
        "Rheumatoid Arthritis",
        "Osteoarthritis",
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Phone-Based Walk With Ease",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2022-04-01",
      "completion_date": "2024-09-10",
      "has_results": true,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 1,
      "location_summary": "Columbia, South Carolina",
      "locations": [
        {
          "city": "Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05289544"
    },
    {
      "nct_id": "NCT07116746",
      "title": "Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout",
        "Gouty Arthritis",
        "Hyperuricemia",
        "Gout Chronic",
        "Refractory Gout",
        "Uncontrolled Gout",
        "Tophaceous Gout"
      ],
      "interventions": [
        {
          "name": "AR882 75 mg",
          "type": "DRUG"
        },
        {
          "name": "XOI Low Dose",
          "type": "DRUG"
        },
        {
          "name": "XOI High Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arthrosi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 15,
      "start_date": "2025-12-03",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 8,
      "location_summary": "Margate, Florida • Miami, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Margate",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07116746"
    },
    {
      "nct_id": "NCT03181828",
      "title": "Manipulating the Gut Microbiome Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urea Cycle Disorder"
      ],
      "interventions": [
        {
          "name": "Acetohydroxamic Acid Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "No treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Nicholas Ah Mew",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 4,
      "start_date": "2017-03-24",
      "completion_date": "2018-06-05",
      "has_results": true,
      "last_update_posted_date": "2021-12-15",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181828"
    },
    {
      "nct_id": "NCT00345657",
      "title": "Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperlipidemia",
        "Mixed Hyperlipidemia",
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Niacin Extended Release/Lovastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "In His Image",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2003-07",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2006-06-28",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 1,
      "location_summary": "Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00345657"
    },
    {
      "nct_id": "NCT00433147",
      "title": "A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gaucher Disease, Type 1",
        "Type 1 Gaucher Disease",
        "Gaucher Disease"
      ],
      "interventions": [
        {
          "name": "Afegostat tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 30,
      "start_date": "2007-03-23",
      "completion_date": "2008-02-19",
      "has_results": true,
      "last_update_posted_date": "2018-09-25",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Coral Springs, Florida • Decatur, Georgia + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00433147"
    },
    {
      "nct_id": "NCT04404530",
      "title": "Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Phenylketonurias"
      ],
      "interventions": [
        {
          "name": "Palynziq",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2019-10-08",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04404530"
    },
    {
      "nct_id": "NCT06545136",
      "title": "Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gaucher Disease, Type 1"
      ],
      "interventions": [
        {
          "name": "FLT201",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Spur Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2024-05-13",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06545136"
    },
    {
      "nct_id": "NCT00920647",
      "title": "A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hunter Syndrome"
      ],
      "interventions": [
        {
          "name": "Control",
          "type": "OTHER"
        },
        {
          "name": "Idursulfase IT (1 mg)",
          "type": "DRUG"
        },
        {
          "name": "Idursulfase IT (10 mg)",
          "type": "DRUG"
        },
        {
          "name": "Idursulfase IT (30 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "3 Years to 18 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2009-11-18",
      "completion_date": "2012-10-29",
      "has_results": true,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-10-14T12:29:00.451Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920647"
    }
  ]
}